ValuEngine cut shares of Bayer (OTCMKTS:BAYRY) from a buy rating to a hold rating in a report issued on Wednesday.

Other analysts have also recently issued research reports about the company. Zacks Investment Research upgraded Bayer from a hold rating to a buy rating and set a $148.00 target price on the stock in a research report on Tuesday, September 19th. BNP Paribas upgraded Bayer from a neutral rating to an outperform rating in a research report on Monday, September 25th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $148.00.

Bayer (OTCMKTS BAYRY) traded up $0.55 during trading on Wednesday, reaching $31.58. The company’s stock had a trading volume of 365,137 shares, compared to its average volume of 346,046. Bayer has a one year low of $26.48 and a one year high of $35.41. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.01 and a current ratio of 1.51. The firm has a market capitalization of $102,500.00, a PE ratio of 28.20, a PEG ratio of 1.94 and a beta of 1.14.

TRADEMARK VIOLATION NOTICE: This news story was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at

About Bayer

Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology.

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with's FREE daily email newsletter.